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Abstract
Background: Escherichia coli lineage ST131 predominates across various spectra of extra-intestinal infections, including
urinary tract infection (UTI). The distinctive resistance profile, diverse armamentarium of virulence factors and rapid global
dissemination of ST131 E. coli makes it an intriguing pathogen. However, not much is known about the prevalence and
genetic attributes of ST131 lineage in Pakistan.
Methods: We estimated prevalence and genetic attributes of E. coli ST131 isolates causing UTI among 155 randomly
selected samples. Samples were analyzed for phylogenetic grouping, O-typing and fumC/fimH typing. Isolates were
further tested for the ESBL and virulence factors using PCR.
Results: Overall, 59% of the UPEC isolates belonged to the phylogenetic group B2, followed by D = 28%, B1 = 8% and
A = 5%. Among 18 different Sequence-types, ST131 was the dominant lineage (n = 71; 46%) out of which 72% of the
isolates were assigned to the phylogenetic group B2, while 61% adhered to the serogroup O25b. FumC/fimH typing
confirmed 49% of the ST131 as H30 sub-types. In this study, significant numbers of the identified ST131 isolates were
MDR and 42% showed ESBL phenotypes, out of which 37% carried bla-CTX-M-15. Moreover, different virulence factors were
detected in following percentages: fimH,155(100%), iutA 86 (55%), feoB 76 (49%), papC 75 (48%), papGII 70 (45%), kpsMTII
40 (26%), papEF 37 (24%), fyuA 37 (24%), usp 22 (14%), papA 20 (13%), sfa/foc20 (13%), hlyA 18 (12%), afa 15 (10%), cdtB 11
(7%), papGI 6 (4%), papGIII 6 (4%), kpsMTIII 4 (3%) and bmaE2 (1%).
Conclusion: Conclusively, this study provides important insight into the genetic and virulence attributes of pandemic
MDR ST131 strains involved in UTIs. It also highlights higher prevalence of ST131-O25b-H30 UPEC isolates in patients,
which was previously unreported from this part of globe.
Keywords: ST131, VF genes, ESBL, UPEC, MDR
Background
Extra-intestinal E. coli is the major cause of urinary tract in-
fections and resistance among UTI strains has been mount-
ing against different antibiotics, including trimethoprim-
sulfamethoxazole, fluoroquinolones extended spectrum
cephalosporins and amoxicillin clavulanic acid [1–3]. Due
to the emergence of specific clonal groups such as ST131,
global dissemination of fluoroquinolone-resistance was
highlighted across different geographical regions [4–6].
Clonal group ST131 predominates across various spectra of
infections including cystitis, pyelonephritis, bacteremia,
meningitis, septic shock, epididymo-orchitis and osteoarti-
cular infection. [7, 8]. In addition, ST131 strains harbor di-
verse armamentarium of virulence factors and their genetic
homogeneity regarding virulence potential and resistance
profile has been widely endorsed [8]. Notably, a subgroup
of ST131 strains, known as H30-Rx has remarkable ten-
dency to encode bla-CTX-M-15 gene [7, 9, 10]. In the current
scenario of global urgency related to the antibiotic resist-
ance, underlying epidemiological factors related to the fit-
ness and fast emergence of ST131 across different regions
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are under intensive scrutiny. However, in Pakistan phylo-
genetic grouping, sequence types, virulence attributes and
antibiotic susceptibility profile of UPEC strains remains un-
explored [11, 12]. Therefore, data related to the clonal types
and resistance profile of the strains involved in urinary tract
infections in Pakistan is extremely scarce. This study fills
the gap and provides important insights into the genetic
and virulence attributes of pandemic MDR ST131 strains
involved in UTIs in Pakistan.
Methods
Sample collection and antibiotic susceptibility testing
Altogether n = 155 identified uropathogenic E. coli
(UPEC) were collected during the period of August 2012
to August 2014, from Pakistan Institute of Medical Sci-
ences. Ethical Review Board (ERB) of Pakistan Institute
of Medical Sciences approved this study. Ethical Review
Board approved verbal consent taken from all the pa-
tients. Important patient data such as name, age, gender,
location was recorded and unique identification number
were assigned to each patient. Samples were from
community-acquired urinary tract infections. Antibiotic
testing and phenotypic detections of ESBL were per-
formed by disc diffusion methods according to the
guidelines CLSI, 2014 [13]. Isolates were tested for the
susceptibility to 12 different classes of antibiotics includ-
ing β-lactamase inhibitors (piperacillin tazobactam,
amoxicillin-clavulanic acid), cephalosporins (ceftazidime,
cefotaxime, ceftriaxone), fluoroquinolone (ciprofloxacin,
levofloxacin), aminoglycosides (amikacin), trimethoprim
sulfonamides, nitrofurantoin, and fosfomycin (BIOANA-
LYSE, Turkey). Control strain E. coli ATCC 25922 was
used in this assay.
Phylogeny, serotyping, and fumC/fimH typing
We used the procedure reported by Clermont et al, 2000
to perform phylogenetic analysis of 155 isolates [14].
FumC/fimHtyping (CH typing) was performed as previ-
ously described [15]. Briefly, PCR amplifications were
carried out in 25 μl (12.5 μl GoTaq DNA polymerase
(Promega), 7.5 μl water, 1 μl bacterial DNA, 2 μl of each
forward and reverse primers). The amplified products
were analyzed on 2% agarose gel. The confirmed PCR
products were purified using PCR purification kit (QIA-
quick, QIAGEN) and all the amplified DNA fragments
were sequenced (ABI 3130, Perkin-Elmer Applied Bio-
systems, Foster City, California). The forward and re-
verse sequences were aligned, trimmed off using Codon
Code Aligner and results were compiled according to
the standard procedures [15, 16]. Additionally, by target-
ing 347 bp of pabB gene fragment, clonal group ST131
was scrutinized for serogroup O25b [17]. Previously
typed O25b-ST131 strains and K-12 E. coli were in-
cluded as experimental controls in this study.
Detection of β-lactamases and virulence factor genes
In order to detect extra-chromosomally encoded ESBL fac-
tors, plasmid DNA was isolated by commercially available
kit (Thermo-Scientific Gene Jet plasmid Miniprep Kit).
ESBL factors including bla-TEM, bla-SHV and genes bla-OXA,
bla-PSE were PCR amplified as described elsewhere [18].
Amplified products were then purified (Gel Band Purifica-
tion Kit, Amersham, USA) and sequencing was done by au-
tomated DNA sequencer (ABI 3130, Perkin-Elmer Applied
Biosystems, Foster City, California). Sequences were re-
ported to the Gene Bank database (accession number;
KX171170–171195). PCR amplifications and sequencing of
bla-CTX-M allele was carried out, bla-CTX-M types were de-
termined by comparing DNA sequences available in the
database [19]. A total of 18 different virulence factors (VF)
corresponding to the main classes of extra-intestinal viru-
lence associated genes (VAGs) including adhesins, toxins,
siderophores, capsular proteins and uropathogenic-specific
protein (usp) were scrutinized in all 155 isolates. VF genes
were amplified by previously reported sets of primers and
amplification conditions [20].
Statistical analysis
The statistical analysis was performed using Graph Pad
Prism, version 7. Both Chi square and Fisher exact tests
were used to assess differences by assuming cut-off value
of P < 0.05 as significant.
Results
Phylogeny and sequence typing
Overall, phylogenetic group B2 showed highest representa-
tion, 92(59%) followed by D 43 (28%), B1 12 (8%) and A
8(5%) (Table 1). Eighteen different sequence types (STs)
of 152 isolates were confirmed, constituting 98% of all the
isolates; the remaining 2% of the isolates were un-typeable.
Clonal group ST131 comparised 71(46%) of all the isolates,
followed by two other lineages, ST405 28(18%) and ST168
16(10%) (Table 2). Majority of the ST131 strains 51(72%)
belonged to the phylogenetic group B2, while 43(61%) were
assigned to serogroup O25b. CH typing confirmed 35(49%)
as ST131-H30 sub-group of strains, out of which 22(31%)
belonged to the serogroup O25b.
MDR among ST131 strains
pt?>Significant number of the isolates assigned to the phylo-
genetic group B2 and D were multi-drug resistant (Table 2).
Similarly, among different STs including ST131, ST405,
ST168, ST29, ST69 and ST89, significant number of the iso-
lates were multi-drug resistant (Table 2). The tendency of
ESBL production and the fluoroquinolone resistance was
relatively higher among ST131 isolates and majority of these
isolates were multi-drug resistant (Table 2). Resistance against
nitrofurantoin was significantly higher among ST131 isolates
in comparison to the other sequence types, whereas one of
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the frequently prevalent sequence types, ST168 strains
were significantly resistant to levofloxacin (Table 3).
Resistance against carbapenemes has not been evalu-
ated for the scrutinized strains in this study; hence it
is beyond the scope of this discussion.
Occurrence of β-lactamases among ST131
Overall, occurrence of ESBL was higher among
clonal group ST131, constituting 42% of the total
ESBL phenotypes (Table 3). Moreover, 78% of the
ESBL phenotypes showed resistance to at least one
Table 1 Distribution of ESBL factors, antibiotic resistance and VF genes in MDR UPEC
Numbers and percentagesof isolates and their respective traits (n = 155)
Resistance traits Total Isolates (n = 155)n (%) Group A
(n = 8)n(%)
Group B1
(n = 12) n(%)
Group B2




ESBL phenotypes 65(42) 1(13) 3(25) 36(39) 25(58) 0.0268
blaCTX-M-15 57(37) 1(13) 3(25) 32(35) 21(49) 0.1333
blaTEM 23(15) 1(13) 3(25) 13(14) 6(14) 0.7823
blaSHV 6(4) 00 00 3(3) 3(7) 0.0907
blaOXA 10(6) 00 1(8) 4(4) 5(12) 0.3610
blaPSE 1(0.6) 00 00 1(1) 00 0.8783
Piperacillin tazobactam 7(5) 00 1(8) 4(4) 2(5) 0.8514
Ceftazidime 96(62) 3(38) 7(58) 54(59) 32(74) 0.1483
Cefotaxime 101(65) 3(38) 7(58) 59(64) 32(74) 0.2028
Ceftriaxone 99(64) 3(38) 8(67) 59(64) 29(67) 0.4001
Ciprofloxacin 95(61) 6(75) 7(58) 56(90) 26(60) 0.4001
Levofloxacin 97(63) 7(88) 8(67) 56(90) 26(60) 0.4929
Amikacin 7(5) 1(13) 00 5(5) 1(2) 0.4920
Gentamicin 47(30) 4(50) 6(50) 24(26) 13(30) 0.2171
Amoxicillin-clavulanic acid 111(72) 5(63) 7(58) 66(72) 26(60) 0.5224
Trimethoprim sulfonamides 130(84) 7(88) 11(92) 77(84) 35(81) 0.8461
Nitrofurantoin 9(6) 1(13) 1(8) 6(7) 1(2) 0.6075
Fosfomycin 15(10) 1(13) 2(17) 8(9) 4(9) 0.8370
fimH 155 (100) 8 (100) 12 (100) 92 (100) 43 (100) > 0.9999
papA 20 (13) 1 (13) 1 (8) 12 (13) 6 (14) 0.9659
papC 75 (48) 2 (25) 8 (67) 43 (47) 22 (51) 0.3092
papEF 37 (24) 0 6 (50) 19 (21) 12 (28) 0.0476
papGI 6 (4) 0 0 3 (3) 3 (7) 0.5699
papGII 70 (45) 2 (25) 7 (58) 37 (40) 24 (53) 0.1695
papGIII 6 (4) 0 0 4 (4) 2 (5) 0.8177
sfa/foc 20 (13) 2 (25) 1 (8) 13 (14) 4 (9) 0.5968
Afa 15 (10) 0 1 (8) 10 (11) 4 (9) 0.7919
bmaE 2 (1) 0 1 (8) 1 (1) 0 0.1466
fyuA 37 (24) 1 (13) 2 (17) 21 (23) 13 (30) 0.5882
iutA 86 (55) 5 (63) 5 (42) 52 (57) 24 (56) 0.7701
feoB 76 (49) 3 (38) 6 (50) 40 (43) 27 (63) 0.1852
kpsmtII 40 (26) 0 4 (33) 21 (23) 15 (35) 0.1438
kpsmtIII 4 (3) 0 1 (8) 3 (3) 0 0.3765
Usp 22 (14) 2 (25) 2 (17) 14 (15) 4 (9) 0.6256
hlyA 18 (12) 1 (13) 3 (25) 6 (7) 8 (19) 0.0908
cdtB 11 (7) 0 3 (25) 6 (7) 2 (5) 0.0758
Distribution of resistance and virulence traits among different phylogroups of uropathogenic E. coli (N = 155). The p values were calculated by comparing different
traits among phylogroups
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fluoroquinolone and 95% were resistant to at least
one cephalosporin. The occurrence of ESBL genes
remained as follows, bla-CTX-M-15, 57(39%), bla-TEM
23(15%) and bla-SHV 6(4%). Prevalence of other β-
lactamases genes such as bla-OXA and bla-PSE 1 remained
6 and 0.6% respectively. In comparison to other sequence
types, overall prevalence of β-lactamases genes was higher
among ST131 strains, 27(38%) of the bla-CTX-M-15,
followed by bla-TEM 8(11%), bla-SHV 3(4%) and bla-OXA
6(8%). Presence of bla-CTX-M-15 was highest (100%) among
ST131 H30-O25b and 91% of the bla-CTX-M-15 positive
ST131 H30-O25b isolates were resistant to fluoroquino-
lones (Data not shown). ESBL producing isolates were fre-
quently found resistant to ceftazidime, cefotaxime,
ceftriaxone, ciprofloxacin, levofloxacin, amoxicillin-
clavulanic acid and trimethoprim sulfonamides (Table 4).
Distribution of VF genes among different sequence types
A total of 18 different virulence factors were scruti-
nized among 155 isolates. Percntages of VF genes
were as follows: fimH,155(100%), iutA86 (55%), feoB
76 (49%), papC 75 (48%), papGII70 (45%), kpsMTII
40 (26%), papEF 37 (24%), fyuA 37 (24%), usp 22
(14%), papA 20 (13%), sfa/foc20 (13%), hlyA 18
(12%), afa 15 (10%), cdtB 11 (7%), papGI 6 (4%),
papGIII 6 (4%), kpsMTIII 4 (3%) and bmaE2 (1%).
Some virulence factors such as sfa/foc, fyuA and
feoB were detected frequently among ST131 isolates
whereas VF-genes papEF, sfa/focand hlyA were fre-
quently associated with H30 sub-clone (Table 5).
Overall, virulence genes such as sfa/foc, fyuA and
feoB were associated significantly (p < 0.05) with
ST131 strains, while papEF had significant presence
among clonal group ST131-H30.
Discussion
E. coli ST131 was reported from three different conti-
nents [8]. However, recently it has become the most pre-
dominant lineage associated with variety of infections
around the globe. ST131 strains have a tendency to har-
bor ESBL enzymes bla-CTX-M-15, which play a significant
role in mounting resistance against β-lactam class of an-
tibiotics [8]. Moreover, ST131 strains show remarkable
resistance to the fluoroquinolones and demonstrate
greater abilities to adhere bladder, kidneys and epithelial
cells [4, 5]. In this study, clonal group ST131 was the
most prevalent lineage, comprising 46% of the isolates
and majority of these isolates (59%) belonged to the
phylogenetic group B2. Prevalence of two other lineages
ST405 and ST168 were 18 and 10% respectively.
Involvement of these lineages in UTIs has been de-
scribed earlier and recently ST405 was confirmed as an
emerging uropathogenic E. coli clone in Saudi Arabia
[21, 22]. Urinary tract infections caused by E. coli pose
considerable challenge and are associated with higher
morbidity and mortality [5]. Due to their resistance
against variety of antibiotics, including β-lactams, ami-
noglycosides and fluoroquinolones, infections caused by
pandemic clonal group ST131 are particularly challen-
ging to treat [23, 24]. In this context, epidemiological
significance of a sub group ST131 H30-Rx has been well
described [5, 25]. In this study, 50% of the ST131 strains
carried H30 variant of fimH gene and 61% belonged to
the serogroup O25b. All the isolates belonging to
the sub-group ST131-H30-O25b carried ESBL bla-
CTX-M-15 however, overall prevalence of these particular
strains constituted only 10% of the total isolates. Resist-
ance against fluoroquinolones in ST131 strains remained
60%, that was remarkably higher. For the treatment of
UTIs commonly prescribed antibiotics include
sulphamethoxazole-trimethoprim and fluoroquinolones.
Table 2 Distribution of MDR and fluoroquinolone resistant MDR
strains in different phylogroups and ST-types
Numbers and percentages of the sequence typed isolates (n = 155)







Group A 8(5) 7(88) 2(25) 0.0117
Group B112(8) 10(83) 5(42) 0.0350
Group B2 92(59) 71(77) 33(36) < 0.0001
Group D 43(28) 36(84) 11(26) < 0.0001
ST131 71(46) 57(82) 22(31) < 0.0001
H30 35(49) 28(80) 10(29) < 0.0001
Non H30 36(51) 29(81) 12(33) < 0.0001
ST405 28(18) 24(86) 10(36) 0.0001
ST168 16(10) 14(88) 7(44) 0.0092
ST2913(8) 9(69) 5(38) 0.1156
ST69 5(3) 5(100) 2(40) 0.0384
ST95 2(1) 2(100) 00
ST31 2(1) 00 00
ST10 2(1) 1(50) 00
ST4482(1) 1(50) 00
ST892(1) 2(100) 1(50) 0.2482
ST7032(1) 2(100) 00







NSC3(2) 2(67) 2(67) > 0.9999
Phylogenetic and sequence type distribution of co-resistance among
uropathogenic E. coli (N = 155). The p values were calculated by comparing
total number of MDR producers and ESBL producers FQR MDR
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However, due to the emerging resistance to these antibi-
otics alternative therapeutic choices such as nitrofuran-
toin, fosfomycin and β-lactam inhibitors can
be prescribed.
In this study, prevalence of ESBL genes was higher
among ST131 and 90% of these strains were resistant to
ceftazidime and cefotaxime. Likewise, resistance to cef-
triaxone was confirmed in 77% of these strains. Because
of their favorable safety, cephalosporins are considered
important therapeutic choice for the treatment of un-
complicated UTIs among pregnant women [26].
Nitrofurantoin is a fluoroquinolone-sparing alternative
antibiotic used for the treatment of uncomplicated cystitis
[27]. In recent years use of nitrofurantoin has increased
steadily, particularly due to the resistance against tri-
methoprim/sulfamethoxazole and aminopencillins.
Contraindication of ciprofloxacin in pregnancy and ad-
verse impact on the gut flora favored the use of nitrofur-
antoin as an alternative treatment option for UTIs. In this
study 13% of the ST-131 strains were resistant to
nitrofurantoin.
We found that majority of the isolates belonging to
the lineages ST405, ST168, ST29, ST69 and ST89
were multi-drug resistant. Percentage of MDR iso-
lates was particularly higher among fluoroquinolones-
resistant ST131 strains. Overall 59% of the isolates
Table 4 Distribution of drug resistance and VF genes among ESBL producers and non ESBLUPEC
Numbers and percentages of the isolates andtheir respective traits
Resistance traits All isolates (n = 155); n(%) Non ESBL producers (n = 90) n(%) ESBL producers (n = 65) n(%) p value
Piperacillin tazobactam 7(5) 4(4) 3(5) > 0.9999
Ceftazidime 96(62) 36(40) 60(92) < 0.0001
Cefotaxime 101(65) 40(44) 61(94) < 0.0001
Ceftriaxone 99(64) 49(54) 50(77) 0.0040
Ciprofloxacin 95(61) 45(50) 50(77) 0.000684
Levofloxacin 97(63) 48(53) 49(75) 0.0051
Amikacin 7(5) 4(4) 3(5) 0.9597
Gentamicin 47(30) 30(33) 17(26) 0.3373
Amoxicillin-clavulanic acid 111(72) 50(56) 61(94) < 0.0001
Trimethoprim sulfonamides 130(84) 67(74) 63(97) 0.0002
Nitrofurantoin 9(6) 6(7) 3(5) 0.5900
Fosfomycin 15(10) 8(9) 7(11) 0.6960
fimH 155 (100) 90 (100) 65 (100) > 0.9999
papA 20 (13) 12 (13) 8 (12) 0.8509
papC 75 (48) 42 (47) 33 (51) 0.6140
papEF 37 (24) 18 (20) 19 (29) 0.1834
papGI 6 (4) 3 (3) 3 (5) 0.6831
papGII 70 (45) 33 (37) 37 (57) 0.0124
papGIII 6 (4) 4 (4) 2 (3) 0.6632
sfa/foc 20 (13) 11 (12) 9 (14) 0.7660
Afa 15 (10) 7 (8) 8 (12) 0.3466
bmaE 2 (1) 1 (1) 1 (2) 0.8246
fyuA 37 (24) 20 (22) 17 (26) 0.5710
iutA 86 (55) 45 (50) 41 (63) 0.1060
feoB 76 (49) 40 (44) 36 (55) 0.1788
kpsmtII 40 (26) 19 (21) 21 (32) 0.1160
kpsmtIII 4 (3) 2 (2) 2 (3) 0.4729
Usp 22 (14) 10 (9) 12 (18) 0.1957
hlyA 18 (12) 7 (8) 11 (17) 0.0795
cdtB 11 (7) 6 (7) 5 (8) 0.8062
Distribution of resistance and virulence traits among ESBL and non-ESBL producing uropathogenic E. coli (N = 155). The p values were calculated by comparing
different traits among ESBL producer’s and non-ESBL producers
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belonged to the phylogenetic group B2. A previous
study from Pakistan confirmed that 50% of the UPEC
isolates belonged to the phylogenetic group B2 [28].
Likewise, another study conducted in Pakistan re-
ported that only 12% of the E. coli strains belonged
to this phylogenetic group. These findings suggest
that prevalence of phylogenetic group B2 may vary
across different regions [29]. Few studies conducted
previously in this region included phylogentic analysis
of UPEC strains.
Phylogenetic group B2 strains are equipped with
various VF genes relating to the extra-intestinal infec-
tions. These genes include P-fimbriae, S-fimbriae, hae-
molysin, aerobactin, K1 and K5 antigens and capsular
antigen genes [30, 31]. A previous report focusing on
the UPEC, in Pakistan described prevalence of various
VF genes, including hlyA, sfaDE, papC,cnf1, eaeA and
afaBC [29] While another study conducted on the rec-
tal floral isolates of Pakistani children confirmed that
virulence factors such as S-fimbriae, haemolysin, K-1
antigens and class III PapG adhesins were either very
rare or completely absent [29]. In current study,
UPEC strains of phylogenetic group B2, carried range
of virulence factors, including genes for adhesins
(fimH 100%, papA 13%, papC 47%, papEF 21% papGI
3%, papGII 40%, papGIII 4%, sfa/foc 14%, afa 11%,
bmaE 1%), toxins (hlyA 7%, cdtB 7%) iron acquisition
system (iutA 57%, feoB43%, fyuA 23%) capsular pro-
teins (kpsMTII 26%, kpsMTIII 3%) and uropathogenic
specific protein (usp 14%). We observed that the gene
papGII was significantly associated with phylogenetic
group B2 strains and association of papGII with py-
elonephritis and bacteraemia in human has been con-
firmed earlier [32–34]. In the current study, fimbriae
associated gene fimH was detected among 100% of the
UPEC isolates Role of fimH in adhesion, invasion and for-
mation of the intracellular bacterial communities (IBCs)
has been described previously and its importance in the
host pathogen interaction was confirmed by higher vul-
nerabilities of premenopausal women to UPEC infections
[35]. In this study genes related to the adhesins (papEF,
sfa/foc) and toxins (hlyA) were found to be strongly asso-
ciated with ST131 H30 sub-clone. Recently hlyA in inter-
action with natural killer (NK) cells of urinary bladder was
described [36]. Likewise, we witnessed significant associ-
ation of the iron acquisition genes ((fyuA and feoB)
with ST131 lineage. The importance of gentic factors re-
lated to the iron acquisition system was shown by strong
upregulation of these genes during UTIs [37]. Generally,
E. coli strains causing UTI share similar properties in
terms of phylogeny, sero-grouping and VF genes. How-
ever, other than genetic attributes of the virulence strains,
host factors may play important role in the outcome of in-
fection [38].
Conclusion
In conclusion it is the first report that highlights MDR
ST131 as a predominant linage associated with UTI in
Pakistan. ST131 and other scrutinized sequence types
having MDR status among UTI isolates in Pakistan indi-
cate considerable constraints on the empirical choice for
the treatment of UTI. Alternative therapies and identifi-
cation of effective prevention strategies–including anti-
biotic stewardship – are needed. As antibiotic resistance
can be transferred from UPEC to other pathogens, more
judicious use of antibiotics is required.
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